

## AAP COVID-19 Vaccine Coding Chart

Vaccine Manufacturer	Patient Age	Cap Color	Vaccine Product	1st Dose Admin	2nd Dose Admin	3rd Dose Admin	Booster Admin	Vaccine Product	Dosing Interval	Unit of Use NDC
Pfizer	≥12 years	Gray	91305	0051A	0052A	0053A	N/A (see 91212)	COVID-19 vaccine, mRNA-LNP, spike protein, PF, 30mcg/0.3 mL dosage, tris-sucrose formulation, for IM use	1st to 2nd Dose: 21 d 2nd to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]): 28 or More Days	59267-1025-1 59267-1025-01
Pfizer	≥12 years	Gray	91312	N/A	N/A	N/A	0124A	COVID-19 vaccine, mRNA-LNP, <b>bivalent</b> spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for IM use	Booster*	59267-0304-1 59267-0304-01 59267-1404-1 59267-1404-01
Pfizer	5-11 years	Orange	91307	0071A	0072A	0073A	N/A (see 91315)	COVID-19 vaccine, mRNA-LNP, spike protein, PF, 10mcg /0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for IM use	1st to 2nd Dose: 21 d 2nd to 3rd Dose (CDC recommended population[s] [eg, immunocompromised ]): 28 or More Days	59267-1055-1 59267-1055-01
Pfizer	5-11years	Orange	91315	N/A	N/A	N/A	0154A	COVID-19 vaccine, mRNA-LNP, <b>bivalent</b> spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for IM use	Booster*	59267-0565-1 59267-0565-01
Pfizer	6 months-4 years	Maroon	91308	0081A	0082A	0083A	N/A	COVID-19 vaccine, mRNA, spike protein, LNP, PF, 3mcg/0.2 mL dose, tris-sucrose formulation	1st to 2nd Dose: 21 d 2nd to 3rd Dose*	59267-0078-1 59267-0078-01 59267-0078-4 59267-0078-04
Moderna	≥12 years	Red Cap Blue Label Border	91301	0011A	0012A	0013A	N/A (see 91313)	COVID-19 vaccine, mRNA-LNP, spike protein, PF, 100 mcg/0.5mL dosage, for IM use	1st to 2nd Dose: 28 d 2nd to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]): 28 or More Days	80777-273-10 80777-0273-10
Moderna	≥12 years	Blue Cap Gray Label Border	91313	N/A	N/A	N/A	0134A	COVID-19 vaccine, mRNA-LNP, spike protein, <b>bivalent</b> , preservative free, 50 mcg/0.5 mL dosage, for IM use	Booster*	80777-282-05 80777-0282-05
Moderna	6-11 years	Blue Cap Purple Label Border	91309	0091A	0092A	0093A	N/A (see 91314)	COVID-19 vaccine, mRNA-LNP, spike protein, PF, 50mcg/0.5 mL dosage, for IM use	1st to 2nd Dose: 1 month 2nd to 3rd Dose: (CDC recommended population[s] [eg, immunocompromised]): 1 month	80777-275-05 80777-0275-05
Moderna	6-11 years	Blue Cap Gray Label Border	91314	N/A	N/A	N/A	0144A	COVID-19 vaccine, mRNA-LNP, spike protein, <b>bivalent</b> , preservative free, 25 mcg/0.25 mL dosage, for IM use	Booster*	80777-282-05 80777-0282-05
Moderna	6 months-5 years	Blue Cap Magenta Label Border	91311	0111A	0112A	0113A	N/A	COVID-19 vaccine, mRNA-LNP, spike protein, PF, 25mcg/0.25 mL dosage, for IM use	1st to 2nd Dose: 1 month 2nd to 3rd Dose: (CDC recommended population[s] [eg, immunocompromised]): 1 month	80777-279-05 80777-0279-05
Janssen	≥18 years		91303	0031A	N/A	N/A	N/A	COVID-19 vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, PF, 5x10 <sup>10</sup> viral particles/0.5mL dosage, for IM use	*primary series is single shot	59676-580-05 59676-0580-05
Novavax	≥12 years		91304	0041A	0042A	N/A	N/A	COVID-19 vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, PF, 5 mcg/0.5 mL dosage, for IM use	1st to 2nd Dose: 21 d	80631-100-01 80631-1000-01
Novavax	≥18 years		91304	N/A	N/A	N/A	0044A	COVID-19 vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, PF, 5 mcg/0.5 mL dosage, for IM use	Booster*	80631-100-01 80631-1000-01

Date: 10.26.2022

\*Refer to [FDA/CDC Guidance](#) and <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html# covid19-vaccines>

COVID-19 vaccine, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease); d, days; IM, intramuscular; PF, preservative-free

\*\*Booster recommendations are based on approval of bivalent boosters as of 10/12/2022. Coding will differ for monovalent boosters used prior to approval of bivalent boosters.